Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
157.17B
Market cap157.17B
Price-Earnings ratio
20.15
Price-Earnings ratio20.15
Dividend yield
6.30%
Dividend yield6.30%
Average volume
42.72M
Average volume42.72M
High today
$27.73
High today$27.73
Low today
$27.09
Low today$27.09
Open price
$27.29
Open price$27.29
Volume
31.31M
Volume31.31M
52 Week high
$27.94
52 Week high$27.94
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

Pfizer(PFE) stock is priced at $27.64, giving the company a market capitalization of 157.17B. It carries a P/E multiple of 20.15 and pays a dividend yield of 6.3%.

As of 2026-03-19, Pfizer(PFE) stock has fluctuated between $27.09 and $27.73. The current price stands at $27.64, placing the stock +2.0% above today's low and -0.3% off the high.

Pfizer(PFE) shares are trading with a volume of 31.31M, against a daily average of 42.72M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.

In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.

PFE News

Simply Wall St 1h
Does Positive TALAPRO‑3 and FOURLIGHT‑1 Data Reframe Pfizer’s Oncology Story And Investment Case?

In recent days, Pfizer reported positive topline data from multiple late-stage trials, including Phase 3 TALAPRO-3 in HRR gene‑mutated metastatic castration‑sen...

Does Positive TALAPRO‑3 and FOURLIGHT‑1 Data Reframe Pfizer’s Oncology Story And Investment Case?
Benzinga 4h
Pfizer Combo Therapy Scores Major Win In Prostate Cancer Trial

Pfizer Talzenna Plus Xtandi Hit Primary Goal On Thursday, the U.S. drug giant reported topline data from the TALAPRO-3 Phase 3 study of Talzenna (talazoparib)...

Pfizer Combo Therapy Scores Major Win In Prostate Cancer Trial
TipRanks 8h
Pfizer’s talzenna plus xtandi shows improved survival in prostate cancer

Pfizer (PFE) announced positive topline results from the Phase 3 TALAPRO-3 study of talzenna – talazoparib -, an oral poly ADP-ribose polymerase, or PARP, inhib...

Analyst ratings

55%

of 29 ratings
Buy
34.5%
Hold
55.2%
Sell
10.3%

More PFE News

TipRanks 1d
Pfizer Advances Early PF-07328948 Liver Study, Adding Quiet Support to PFE’s Pipeline Story

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is running a Phase 1 study called “A PHASE 1, OPEN-LABEL, SINGLE-DOSE,...

TipRanks 1d
Pfizer Ends Early-Stage Melanoma Study, Trimming One Oncology Bet But Not the Broader Pipeline

Pfizer Inc (PFE) announced an update on their ongoing clinical study. The phase 1 study “AN OPEN-LABEL PHASE 1 STUDY TO INVESTIGATE PF-08046031 IN ADULTS WITH...

Nasdaq 1d
The Best Healthcare Stocks to Buy With $50 Right Now

Key Points Pfizer and Novo Nordisk look cheap in more ways than one. Pipeline progress could help improve their financial results. Exelixis is a small but su...

The Best Healthcare Stocks to Buy With $50 Right Now
Simply Wall St 1d
Pfizer Phase 2 Wins Reshape Growth Story In Oncology And Immunology

Pfizer (NYSE:PFE) reported positive randomized Phase 2 results for atirmociclib, its next generation CDK4 inhibitor, in advanced or metastatic breast cancer. T...

Pfizer Phase 2 Wins Reshape Growth Story In Oncology And Immunology
Benzinga 2d
Pfizer Touts Promising Survival Data Without Worsening For Advanced Breast Cancer Patients

Pfizer Inc. (NYSE:PFE) on Tuesday announced topline results from the Phase 2 FOURLIGHT-1 study in pretreated metastatic breast cancer patients. The trial, whic...

Pfizer Touts Promising Survival Data Without Worsening For Advanced Breast Cancer Patients
Nasdaq 2d
The Smartest Dividend Stocks to Buy With $150 Right Now

Anytime is a great time to invest in stocks. The catch is that you must choose the right stocks. The current market dynamics, including high volatility and wor...

The Smartest Dividend Stocks to Buy With $150 Right Now
Seeking Alpha 2d
Pfizer succeeds in mid-stage trial for breast cancer therapy

Pfizer (PFE) announced on Tuesday that its investigational breast cancer therapy, atirmociclib, as part of a combination regimen, reached the main goal in a lat...

Pfizer succeeds in mid-stage trial for breast cancer therapy

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.